Impacting global healthcare with rapid, easy to use, point-of-care tests.
Rapid Pathogen Screening, Inc. (RPS) is an emerging biotechnology company strategically focused on designing, developing, and delivering novel point-of-care tests for infectious diseases and inflammatory conditions as well as bio-terrorism and chemical nerve agent blood toxins. RPS products are developed using a unique and innovative patented technology platform which the company can utilize to develop a variety of cost-effective tests.
RPS tests allow healthcare providers to more accurately diagnose diseases, provide appropriate and timely treatment, and reduce healthcare costs associated with spread of disease and unnecessary treatment methods.
